Summary
Access to genetic resources and the fair and equitable sharing of benefits (ABS) has become one of the most studied and reflected upon concepts in the Convention on Biological Diversity (CBD) process since 1992. But despite all of this attention, it is still not clear what is included under the scope of ABS. In other words: what does ABS actually cover?
The scope of ABS has shifted and changed over the years, making implementation at the national level challenging. Today, the range of activities and resources covered could include:
- Biotrade, biological resources and non-timber forest products (NTFPs)
- Genetic resources sourced for the biotechnology industry or as natural products for the pharmaceutical industry, increasingly from microorganisms
- Traditional knowledge, innovations and practices associated with genetic resources
- Genetic sequence data, or Digital Sequence Information (DSI), the subject of much attention within the CBD these days
Identifying what falls within ABS, and the costs and benefits of narrow vs broad approaches, has significant implications for Nagoya Protocol implementation. Following from the issue of scope grows a question central to ABS implementation: is a new regulatory framework that covers the full range of products and uses the best approach, or might an approach that integrates ABS principles of fairness and equity into existing laws and policies – “mainstreaming” ABS – possible?
This webinar will explore some of these issues. It will run for 1.5 hours, and will include an introduction, followed by four, 10 minute presentations, and a 30 minute Q&A session.